Grufity logo
Grufity logo

Latest Affinity Asset Advisors, LLC Stock Portfolio

$2.21Billion | No. of Holdings #101

Affinity Asset Advisors, LLC Performance

2026 Q2+19.97%
YTD+31.02%
2025+46.96%

About Affinity Asset Advisors, LLC and 13F Hedge Fund Stock Holdings

Affinity Asset Advisors, LLC is a hedge fund based in New York, NY. On 2026-08-13, the fund reported it's updated stock portfolio. In the 13F Holdings report, Affinity Asset Advisors, LLC reported an equity portfolio of $2.2 Billions as of 30 Jun, 2026. <br><br> The top stock holdings of Affinity Asset Advisors, LLC are ROIV, , AGLE. The fund has invested 6% of it's portfolio in ROIVANT SCIENCES LTD and 5.9% of portfolio in APOGEE THERAPEUTICS INC. <br><br> The fund managers got completely rid off CENTESSA PHARMACEUTICALS PLC (CNTA), ARCELLX INC (ACLX) and TERNS PHARMACEUTICALS INC (TERN) stocks. They significantly reduced their stock positions in ORCHESTRA BIOMED HLDGS INC, NEXTCURE INC (NXTC) and TEVA PHARMACEUTICAL INDS LTD (TEVA). Affinity Asset Advisors, LLC opened new stock positions in FIRST TRACKS BIOTHERAPEUTICS, IDEAYA BIOSCIENCES INC (IDYA) and UNIQURE NV (QURE). The fund showed a lot of confidence in some stocks as they added substantially to EQUILLIUM INC (EQ), ALECTOR INC (ALEC) and SAGIMET BIOSCIENCES INC.
Affinity Asset Advisors, LLC Equity Portfolio Value
Last Reported on: 13 Aug, 2026
$2.21Billion
  as of Aug 13, 2026

Affinity Asset Advisors, LLC Annual Return Estimates Vs S&P 500

Our best estimate is that Affinity Asset Advisors, LLC made a return of 19.97% in the last quarter. In trailing 12 months, it's portfolio return was 104.44%.
  • Performance
  • S&P 500

New Buys

Ticker$ Bought
first tracks biotherapeutics40,884,100
ideaya biosciences inc14,908,000
odyssey therapeutics inc14,338,300
uniqure nv8,060,500
ascendis pharma a/s8,001,600
assembly biosciences inc5,221,200
hemab therapeutics hldgs inc5,069,840
research alliance corp iii3,959,000
New stocks bought by Affinity Asset Advisors, LLC

Additions

Ticker% Inc.
equillium inc234
alector inc202
sagimet biosciences inc187
sab biotherapeutics inc165
relay therapeutics inc162
belite bio inc153
revolution medicines inc150
macrogenics inc143
Additions to existing portfolio by Affinity Asset Advisors, LLC

Reductions

Ticker% Reduced
orchestra biomed hldgs inc-91.7
nextcure inc-82.65
teva pharmaceutical inds ltd-73.29
compass pathways plc-72.83
mbx biosciences inc-50.00
spyglass pharma inc-47.37
zura bio ltd-42.9
anaptysbio inc-41.41
Affinity Asset Advisors, LLC reduced stake in above stock

Sold off

Ticker$ Sold
celcuity inc-7,314,000
wave life sciences ltd-10,162,500
centessa pharmaceuticals plc-55,608,000
engene holdings inc-4,156,620
terns pharmaceuticals inc-29,661,900
arcellx inc-41,652,600
kezar life sciences inc-1,699,740
bridgebio pharma inc-11,139,000
Affinity Asset Advisors, LLC got rid off the above stocks

Sector Distribution

Affinity Asset Advisors, LLC has about 68.7% of it's holdings in Healthcare sector.

  • Healthcare
  • Others
Sector%
Healthcare68.7
Others31.3

Market Cap. Distribution

Affinity Asset Advisors, LLC has about 14.6% of it's portfolio invested in the large-cap and mega-cap stocks.

  • MID-CAP
  • UNALLOCATED
  • LARGE-CAP
  • SMALL-CAP
  • MICRO-CAP
Category%
MID-CAP36.2
UNALLOCATED31.3
LARGE-CAP14.6
SMALL-CAP14.6
MICRO-CAP3

Stocks belong to which Index?

About 38.6% of the stocks held by Affinity Asset Advisors, LLC either belong to S&P 500 or RUSSELL 2000 index.

  • Others
  • RUSSELL 2000
Index%
Others61.4
RUSSELL 200038.6
Top 5 Winners (%)%
CMPS
compass pathways plc
99.1 %
q32 bio inc
98.4 %
TVTX
travere therapeutics inc
91.2 %
oruka therapeutics inc
81.0 %
anteris technologies global
77.5 %
Top 5 Winners ($)$
apogee therapeutics inc
55.2 M
AGLE
spyre therapeutics inc
49.0 M
ANAB
anaptysbio inc
34.1 M
ROIV
roivant sciences ltd
25.2 M
oruka therapeutics inc
25.1 M
Top 5 Losers (%)%
RCKT
rocket pharmaceuticals inc
-76.4 %
NXTC
nextcure inc
-49.9 %
adagio med hldgs inc
-43.3 %
lenz therapeutics inc
-37.9 %
INSM
insmed inc
-31.7 %
Top 5 Losers ($)$
INSM
insmed inc
-32.1 M
lexeo therapeutics inc
-5.9 M
FBRX
forte biosciences inc
-5.0 M
perspective therapeutics inc
-2.8 M
TYRA
tyra biosciences inc
-1.5 M

Affinity Asset Advisors, LLC Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Affinity Asset Advisors, LLC

Affinity Asset Advisors, LLC has 101 stocks in it's portfolio. About 39.4% of the portfolio is in top 10 stocks. INSM proved to be the most loss making stock for the portfolio. was the most profitable stock for Affinity Asset Advisors, LLC last quarter.

$2.04BTotal Value
114Positions
13 Aug, 2026Last Reported
Current holdings of Current Stock Holdings of Affinity Asset Advisors, LLC, last reported on 13 Aug, 2026. Select a row with a linked ticker to view its historical trend.
ExpandHoldingsorted ascending% PortfolioShares Held$ Value% Change
ASND
Ascendis Pharma A/S

Ascendis Pharma A/S

ASND
Affinity Asset Advisors, LLC's holding in Ascendis Pharma A/S over time
0%0.00
$0.00
0%
decreased 100 percentsold off
BLTE
Belite Bio Inc

Belite Bio Inc

BLTE
Affinity Asset Advisors, LLC's holding in Belite Bio Inc over time
1.15%165,000
$25.41M
1.15%
increased 153.85 percentadded
CMPS
Compass Pathways Plc

Compass Pathways Plc

CMPS
Affinity Asset Advisors, LLC's holding in Compass Pathways Plc over time
0.19%301,183
$4.26M
0.19%
decreased 72.83 percentreduced